drugset / Trial / NCT03100591
A Study to Evaluate ACT-132577 in Healthy Male Subjects
NaSingle-groupOpen-labelOther
Summary
The primary purpose of this study is to investigate the rate and routes (urine and feces) of elimination of ACT-132577, and the mass balance in urine and feces
Timeline
- Start
- 2017-03-28
- Primary completion
- 2017-04-18
- Completion
- 2017-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprocitentan | Small molecule | 25 mg | Oral |
Indications
No indication recorded.